Kanghong Pharmaceutical: Subsidiary purchases 1.7 billion yuan of China Bank's wealth management products.

Kanghong Pharmaceutical announced that its subsidiary Kanghong Biotechnology recently used 1.7 billion yuan of its own funds to purchase RMB structured deposit products from the China Bank Chengdu Wuhou Branch. The product type is a principal-guaranteed floating income type, with the income starting on June 9, 2026. In the twelve months prior to the announcement date, the company and its controlling subsidiaries have collectively used 2.045 billion yuan of idle funds to purchase bank principal-guaranteed financial products that have not yet matured, without exceeding the authorized amount by the shareholders' meeting. The company stated that the investment does not affect the main business and can improve the efficiency of fund utilization.